Data on ElectroCore's Vagal Nerve Stimulation Therapy GammaCore Selected for an Oral Presentation at the 65th American Academy of Neurology Annual Meeting

-- Results show GammaCore to be an effective, well-tolerated treatment for acute treatment of episodic migraine

News provided by

Mar 13, 2013, 09:38 ET

MORRIS PLAINS, N.J., March 13, 2013 /PRNewswire/ -- ElectroCore^®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious medical conditions including primary headaches, announced today that data demonstrating the efficacy of its GammaCore^® therapy as an acute treatment for migraine was accepted for an oral presentation at the American Academy of Neurology Annual Meeting March 16-23 in San Diego.

The open-label pilot study "Non-Invasive Neurostimulation of the Vagus Nerve with the GammaCore Device for the Relief of Symptoms Associated with Migraine" was conducted by Peter Goadsby, M.D., director of the University of California San Francisco Headache Center; Roger Cady, M.D., founder of the Headache Care Center; Brian Grosberg, M.D., director of the Montefiore Headache Center and Alexander Mauskop, founder and director of the New York Headache Center. The data will be presented on Wednesday, March 20, at 4:39 p.m. PDT in the Moderated Platform Session S40: Headache: Clinical.

"The study's results suggest GammaCore's non-invasive vagal nerve stimulation to potentially be an effective and well-tolerated acute treatment for migraine," said J.P. Errico, CEO of ElectroCore. "One-third of all patients who were treated while experiencing mild, moderate or severe pain were pain free at two hours."

In the study, 27 enrolled participants treated an acute migraine with a portable nVNS device (GammaCore). Treatment consisted of two, 90-second doses, at 15-minute intervals delivered to the right cervical branch of the vagus nerve. Two-thirds of patients treated at mild pain were pain free at two hours. Treatment related adverse effects were limited.

"We are currently enrolling our FDA-approved chronic migraine prevention study at several sites across the U.S., with an initial readout expected later this year," said Errico. "We believe the study will further demonstrate the efficacy of GammaCore as an important new treatment option for the many Americans who suffer from migraine."

For more information about ElectroCore's AAN presentation, visit http://www.abstracts2view.com/aan/view.php?nu=AAN13L_S40.004.

About GammaCore®
GammaCore is a non-invasive, vagus nerve stimulator that produces a mild electrical signal which is transmitted to the vagus nerve through the skin. It's indicated for the acute and/or prophylactic treatment of migraine, cluster headache, and medication overuse headache (MOH) in adults. GammaCore is currently available in the European Union, South Africa, India, New Zealand, Australia, Colombia and Malaysia for the acute and/or prophylactic treatment of migraine, cluster headache, and MOH in adults. GammaCore is available in Canada for cluster headache only.

About ElectroCore®
ElectroCore is a healthcare company focused on non-invasive neuromodulation therapies for the treatment of diseases and disorders. The company has developed non-invasive Vagal Nerve Simulation (nVNS) therapies intended to treat and/or prevent symptoms of a number of highly prevalent and disabling conditions. ElectroCore currently has three commercial products on the market: GammaCore®, AlphaCore®, and GammaCore VET™. The company is headquartered in Morris Plains, NJ, with international offices in Stockholm, Sweden, Hamilton, Bermuda, and Sydney, Australia.

For more information, visit: http://www.electrocoremedical.com/.

SOURCE ElectroCore Medical